CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
Hydroxocobalamin +1 moredrug
Likely dose
Hydroxocobalamin 5gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04054999
NCT04054999Phase 4Completed
CompareCT.gov

The Efficacy of Intravenous Hydroxocobalamin Versus Methylene Blue as Treatment for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

Mayo Clinic·interventional·Posted Aug 13, 2019·Updated Jun 24, 2024

In Brief

A Phase 4 clinical trial evaluating Hydroxocobalamin and Methylene Blue for Vasoplegic Syndrome and Liver Transplant; Complications. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVasoplegic Syndrome, Liver Transplant; Complications
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedAug 13, 2019
Enrollment StartNov 30, 2019
Primary CompletionFeb 27, 2023
Study CompletionFeb 27, 2024
TodayJul 3, 2026
Enrollment to primary: 3.2 yearsPosted 6.9 years ago

Interventions

Hydroxocobalamindrug

Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes

Methylene Bluedrug

Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes